Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model

Journal of Virology

Volumn 83, Issue 20, 2009, Pages 10664-10676

  Kwant Mitchell, Amanda ^a   Ashkar, Ali A ^a   Rosenthal, Kenneth L ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; CORD BLOOD STEM CELL TRANSPLANTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; GENITAL SYSTEM; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPH NODE; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; VACCINATION; VIRUS REPLICATION;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNIZATION; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; UMBILICAL CORD;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 70349728566     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02584-08     Document Type: Article

References (70)

1. Ashkar, A. A., and K. L. Rosenthal. 2003. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J. Virol. 77:10168-10171.
2. Ashley, R. L., L. Corey, J. Dalessio, P. Wilson, M. Remington, G. Barnum, and P. Trethewey. 1994. Protein-specific cervical antibody responses to primary genital herpes simplex virus type 2 infections. J. Infect. Dis. 170:20-26.
3. Ashley, R. L., F. M. Crisostomo, M. Doss, R. E. Sekulovich, R. L. Burke, M. Shaughnessy, L. Corey, N. L. Polissar, and A. G. Langenberg. 1998. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine. J. Infect. Dis. 178:1-7.
4. -/- mice. Proc. Natl. Acad. Sci. USA 103:15951-15956.
5. -/- (RAG-hu) mice. Virology 373:342-351.
6. -/- (RAG-hu) mouse model. Retrovirology 3:76.
7. Bernstein, D. I., and L. R. Stanberry. 1999. Herpes simplex virus vaccines. Vaccine 17:1681-1689.
8. Corey, L. 2007. Herpes simplex virus type 2 and HIV-1: the dialogue between the 2 organisms continues. J. Infect. Dis. 195:1242-1244.
9. Corey, L. 2007. Synergistic copathogens - HIV-1 and HSV-2. N. Engl. J. Med. 356:854-856.
10. Corey, L., A. G. Langenberg, R. Ashley, R. E. Sekulovich, A. E. Izu, J. M. Douglas, Jr., H. H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A. A. Adimora, P. Leone, C. L. Dekker, R. L. Burke, W. P. Leong, S. E. Straus, et al. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282:331-340. (Pubitemid 29350487)
11. Corey, L., and A. Wald. 1999. Genital herpes, p. 285-312. In K. K. Holmes, P.-A. Mardh, P. F. Sparling, S. M. Lemon, W. E. Stamm, P. Piot, and J. N. Wasserheit (ed.), Sexually transmitted diseases. McGraw-Hill, New York, NY.
12. Cravens, P. D., M. W. Melkus, A. Padgett-Thomas, M. Islas-Ohlmayer, P. M. M. Del, and J. V. Garcia. 2005. Development and activation of human dendritic cells in vivo in a xenograft model of human hematopoiesis. Stem Cells 23:264-278.
13. Cunningham, A. L., A. L. Mindel, and D. E. Dwyer. 2001. Epidemiology of sexually transmitted diseases, p. 3-42. In L. R. Stanberry and D. I. Bernstein (ed.), Sexually transmitted diseases: vaccines, prevention and control. Academic Press, London, United Kingdom.
14. Cunningham, A. L., R. R. Turner, A. C. Miller, M. F. Para, and T. C. Merigan. 1985. Evolution of recurrent herpes simplex lesions. An immunohistologic study. J. Clin. Investig. 75:226-233.
15. Dalloul, A., E. Oksenhendler, O. Chosidow, P. Ribaud, G. Carcelain, S. Louvet, P. Massip, P. Lebon, and B. Autran. 2004. Severe herpes virus (HSV-2) infection in two patients with myelodysplasia and undetectable NK cells and plasmacytoid dendritic cells in the blood. J. Clin. Virol. 30:329-336.
16. Dudley, K. L., N. Bourne, and G. N. Milligan. 2000. Immune protection against HSV-2 in B-cell-deficient mice. Virology 270:454-463. (Pubitemid 30333692)
17. Freeman, E. E., H. A. Weiss, J. R. Glynn, P. L. Cross, J. A. Whitworth, and R. J. Hayes. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83.
18. Gallichan, W. S., and K. L. Rosenthal. 1998. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177:1155-1161.
19. Gallichan, W. S., R. N. Woolstencroft, T. Guarasci, M. J. McCluskie, H. L. Davis, and K. L. Rosenthal. 2001. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166:3451-3457.
20. Guenechea, G., O. I. Gan, C. Dorrell, and J. E. Dick. 2001. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat. Immunol. 2:75-82.
21. Hesselton, R. M., D. L. Greiner, J. P. Mordes, T. V. Rajan, J. L. Sullivan, and L. D. Shultz. 1995. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J. Infect. Dis. 172:974-982.
22. +-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. Blood 90:85-96.
23. nullmouse: an excellent recipient mouse model for engraftment of human cells. Blood 100:3175-3182.
24. Jones, C. A., and A. L. Cunningham. 2004. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes 11:12-17.
25. Kapiga, S. H., N. E. Sam, H. Bang, Q. Ni, T. T. Ao, I. Kiwelu, S. Chiduo, U. Ndibe, G. Seage III, P. Coplan, J. Shao, Z. F. Rosenberg, and M. Essex. 2007. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J. Infect. Dis. 195:1260-1269.
26. + cells. Blood 99:1620-1626.
27. Koelle, D. M., H. Abbo, A. Peck, K. Ziegweid, and L. Corey. 1994. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J. Infect. Dis. 169:956-961.
28. Koelle, D. M., and L. Corey. 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96-113.
29. Koelle, D. M., J. C. Gonzalez, and A. S. Johnson. 2005. Homing in on the cellular immune response to HSV-2 in humans. Am. J. Reprod. Immunol. 53:172-181.
30. Koelle, D. M., C. M. Posavad, G. R. Barnum, M. L. Johnson, J. M. Frank, and L. Corey. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Investig. 101:1500-1508.
31. Kozlowski, P. A., S. Cu-Uvin, M. R. Neutra, and T. P. Flanigan. 1997. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 65:1387-1394.
32. Kozlowski, P. A., S. B. Williams, R. M. Lynch, T. P. Flanigan, R. R. Patterson, S. Cu-Uvin, and M. R. Neutra. 2002. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. 169:566-574.
33. -/- (RAG-hu) mice. Virology 369:143-152.
34. Kwant, A., and K. L. Rosenthal. 2004. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22:3098-3104. (Pubitemid 39037213)
35. Langenberg, A. G., L. Corey, R. L. Ashley, W. P. Leong, S. E. Straus, et al. 1999. A prospective study of new infections with herpes simplex virus type 1 and type 2. N. Engl. J. Med. 341:1432-1438.
36. Lowry, P. A., L. D. Shultz, D. L. Greiner, R. M. Hesselton, E. L. Kittler, C. Y. Tiarks, S. S. Rao, J. Reilly, J. H. Leif, H. Ramshaw, F. M. Stewart, and P. J. Quesenberry. 1996. Improved engraftment of human cord blood stem cells in NOD/LtSz-scid/scid mice after irradiation or multiple-day injections into unirradiated recipients. Biol. Blood Marrow Transplant. 2:15-23.
37. McClelland, R. S., C. C. Wang, J. Overbaugh, B. A. Richardson, L. Corey, R. L. Ashley, K. Mandaliya, J. Ndinya-Achola, J. J. Bwayo, and J. K. Kreiss. 2002. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 16:2425-2430. (Pubitemid 35471690)
38. McDermott, M. R., L. J. Brais, and M. J. Evelegh. 1990. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2. J. Gen. Virol. 71(Pt. 7):1497-1504.
39. McDermott, M. R., P. L. Brais, G. C. Ploettsche, M. J. Evelegh, and C. H. Goldsmith. 1987. Expression of immunity to intravaginal herpes simplex virus type 2 infection in the genital tract and associated lymph nodes. Arch. Virol. 93:51-68.
40. Mertz, G. J., O. Schmidt, J. L. Jourden, M. E. Guinan, M. L. Remington, A. Fahnlander, C. Winter, K. K. Holmes, and L. Corey. 1985. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex. Transm. Dis. 12:33-39.
41. Milligan, G. N., and D. I. Bernstein. 1995. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology 212:481-489.
42. Milligan, G. N., and D. I. Bernstein. 1995. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology 206:234-241.
43. Milligan, G. N., and D. I. Bernstein. 1997. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229:259-268.
44. Milligan, G. N., D. I. Bernstein, and N. Bourne. 1998. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160:6093-6100. (Pubitemid 28298073)
45. Nagot, N., A. Ouedraogo, V. Foulongne, I. Konate, H. A. Weiss, L. Vergne, M. C. Defer, D. Djagbare, A. Sanon, J. B. Andonaba, P. Becquart, M. Segondy, R. Vallo, A. Sawadogo, P. Van de Perre, and P. Mayaud. 2007. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J. Med. 356:790-799.
46. + hematopoietic progenitors. Blood 102:3302-3310.
47. Parr, E. L., J. J. Bozzola, and M. B. Parr. 1998. Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus. J. Reprod. Immunol. 38:15-30.
48. Parr, E. L., and M. B. Parr. 1998. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J. Virol. 72:5137-5145.
49. Parr, M. B., G. R. Harriman, and E. L. Parr. 1998. Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice. Immunology 95:208-213. (Pubitemid 28459383)
50. Parr, M. B., and E. L. Parr. 2000. Immunity to vaginal herpes simplex virus-2 infection in B-cell knockout mice. Immunology 101:126-131.
51. Parr, M. B., and E. L. Parr. 1998. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes. J. Virol. 72:2677-2685. (Pubitemid 28175502)
52. Parr, M. B., and E. L. Parr. 2003. Vaginal immunity in the HSV-2 mouse model. Int. Rev. Immunol. 22:43-63.
53. Patel, R., and D. R. Harper. 1998. Subclinical herpes virus reactivation and latency. Curr. Opin. Infect. Dis. 11:31-35.
54. Posavad, C. M., D. M. Koelle, and L. Corey. 1998. Tipping the scales of herpes simplex virus reactivation: the important responses are local. Nat. Med. 4:381-382.
55. Reynolds, S. J., A. R. Risbud, M. E. Shepherd, J. M. Zenilman, R. S. Brookmeyer, R. S. Paranjape, A. D. Divekar, R. R. Gangakhedkar, M. V. Ghate, R. C. Bollinger, and S. M. Mehendale. 2003. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J. Infect. Dis. 187:1513-1521.
56. Schacker, T., A. J. Ryncarz, J. Goddard, K. Diem, M. Shaughnessy, and L. Corey. 1998. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280:61-66. (Pubitemid 28414998)
57. Shultz, L. D., P. A. Schweitzer, S. W. Christianson, B. Gott, I. B. Schweitzer, B. Tennent, S. McKenna, L. Mobraaten, T. V. Rajan, D. L. Greiner, et al. 1995. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154:180-191.
58. Smith, P. M., R. M. Wolcott, R. Chervenak, and S. R. Jennings. 1994. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-gamma (IFN-gamma). Virology 202:76-88.
59. Smyth, M. J., E. Cretney, M. H. Kershaw, and Y. Hayakawa. 2004. Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 202:275-293.
60. Staats, H. F., S. P. Montgomery, and T. J. Palker. 1997. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum Retrovir. 13:945-952.
61. Stanberry, L. R. 2004. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11(Suppl. 3):161A-169A.
62. + T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. 204:705-714.
63. Torseth, J. W., and T. C. Merigan. 1986. Significance of local gamma interferon in recurrent herpes simplex infection. J. Infect. Dis. 153:979-984.
64. Traggiai, E., L. Chicha, L. Mazzucchelli, L. Bronz, J. C. Piffaretti, A. Lanzavecchia, and M. G. Manz. 2004. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304:104-107. (Pubitemid 38451466)
65. Watanabe, S., K. Terashima, S. Ohta, S. Horibata, M. Yajima, Y. Shiozawa, M. Z. Dewan, Z. Yu, M. Ito, T. Morio, N. Shimizu, M. Honda, and N. Yamamoto. 2007. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rγ null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 109:212-218. (Pubitemid 46070123)
66. Yajima, M., K. Imadome, A. Nakagawa, S. Watanabe, K. Terashima, H. Nakamura, M. Ito, N. Shimizu, M. Honda, N. Yamamoto, and S. Fujiwara. 2008. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J. Infect. Dis. 198:673-682.
67. Yasukawa, M., and J. M. Zarling. 1983. Autologous herpes simplex virus-infected cells are lysed by human natural killer cells. J. Immunol. 131:2011-2016.
68. + T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood 112:3671-3678.
69. Zhang, B., Z. Duan, and Y. Zhao. 2009. Mouse models with human immunity and their application in biomedical research. J. Cell. Mol. Med. 13:1043-1058.
70. + T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 204:595-603.